NASH Biomarker Market

Non-alcoholic steatohepatitis (NASH) — a type of non-alcoholic fatty liver disease (NAFLD), is the liver inflammation and damage caused by a buildup of fat in the liver. At present, no single test can diagnose non-alcoholic steatohepatitis. However, the doctor diagnoses the patient based on signs and symptoms. Healthcare professionals use the patient’s medical history, conduct a physical exam, and tests such as blood tests, imaging tests, and liver biopsy in order to diagnose the NASH. Major factors characterizing the market growth are the increasing prevalence of diabetes and obesity, growing demand for non-invasive tests, and rising public and private sector initiatives to increase awareness about NASH. On the contrary, the presence of stringent regulations by the US FDA for the qualification of biomarkers and other medical product development tools are anticipated to restrict the market growth during the forecast period.

The global NASH biomarkers market has been segmented based on type, end user, and region. The global NASH biomarkers market was valued at USD 586.9 million in 2018, and the market is estimated to grow at USD 1,960.6 million by 2024. In 2018, the Americas accounted for the largest market share of 51.9% with a market value of USD 304.3 million, followed by Europe with a market value of USD 188.1 million in 2018.

Based on type, the serum biomarkers segment accounted for the largest market share of 36.9% in 2018, with a market value of USD 216.4 million, which is projected to register a CAGR of 21.13% during the forecast period.

On the basis of end user, the pharmaceutical companies and CROs segment dominated the market and accounted for a share of 38.6% in 2018, with a market value of USD 226.7 million, which is anticipated to register a CAGR of 21.24% over the forecast period.